Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, July 26 '25)

Image
By G.M.

 


    Am J Respir Crit Care Med

  1. LAUTRETTE A, Cadoret M, Richard JC, Schwebel C, et al
    Impact of Visitation Restrictions in ICU on Psychological Symptoms in Family Members: Experience of the COVID-19 Pandemic.
    Am J Respir Crit Care Med. 2025 Jul 23. doi: 10.1164/rccm.202412-2470.
    PubMed         Abstract available


    Clin Infect Dis

  2. AKANDE ET, Fowotade AA, Odih EE, Oaikhena AO, et al
    Genomic Surveillance of SARS-CoV-2 in Ibadan, Oyo State, Nigeria.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  3. STREINU-CERCEL A, Castagna A, Chang SC, Chen YS, et al
    Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
    Clin Infect Dis. 2025 Jul 22:ciaf406. doi: 10.1093.
    PubMed         Abstract available

  4. BOSCOLO-RIZZO P, Spinato G, De Colle R, Maniaci A, et al
    Five-Year Longitudinal Assessment of Self-reported COVID-19-Related Chemosensory Dysfunction.
    Clin Infect Dis. 2025 Jul 23:ciaf331. doi: 10.1093.
    PubMed        

  5. SUBIDO-CARINO MT, Donadel M, Asi LD, Ariola-Ramos MS, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence, Illness Recall, and Work Absenteeism Among Healthcare Workers: A Facility-Based Cross-Sectional Study in the Philippines, 2021.
    Clin Infect Dis. 2025 Jul 23:ciaf342. doi: 10.1093.
    PubMed         Abstract available

  6. MA KC, Surie D, Zhu Y, Grijalva CG, et al
    Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus.
    Clin Infect Dis. 2025 Jul 24:ciaf405. doi: 10.1093.
    PubMed         Abstract available

  7. CHISSUMBA RM, Kwatra G, Ramgi P, Enosse M, et al
    Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  8. KANG SSY, Tadesse BT, Jeon HJ, Fallah MP, et al
    Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  9. KIM CL, Thwe TT, Espinoza LMC, Sugimoto JD, et al
    Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  10. RAMGI P, Siribie M, Rakotozandrindrainy N, Bule O, et al
    Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  11. RAKOTOZANDRINDRAINY N, Kang SSY, Wandji Nana LR, Sugimoto JD, et al
    COVID-19 Surveillance in Madagascar and Urban Burkina Faso: Addressing Underreporting of Disease Burden Through Integrative Analysis of Diverse Data Streams.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  12. CAPITINE IU, Aziz AB, Manhica A, Tivane I, et al
    Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  13. DE SCHACHT C, Capitine IU, Lucas C, Muteerwa A, et al
    Importance of Targeted Communication Strategies During COVID-19 Vaccination Campaigns in Mozambique: Results of a Mixed-Methods Acceptability Study.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available


    Emerg Infect Dis

  14. LEGRAND NM, Bull RA, Hajarizadeh B, Lloyd AR, et al
    Surveillance of Viral Respiratory Infections within Maximum-Security Prison, Australia.
    Emerg Infect Dis. 2025;31:1527-1536.
    PubMed         Abstract available

  15. ROSE EB, Paden CR, Cook PW, Ma KC, et al
    Estimated COVID-19 Periodicity and Correlation with SARS-CoV-2 Spike Protein S1 Antigenic Diversity, United States.
    Emerg Infect Dis. 2025;31:1573-1579.
    PubMed         Abstract available

  16. PARK JS, Kim GJ, Lee SW
    Optimal Timing for Expanding Diagnostic Laboratories, South Korea.
    Emerg Infect Dis. 2025;31:1-8.
    PubMed         Abstract available

  17. WILSON-HENJUM G, Root JJ, Worgo A, Chandler J, et al
    Community-Scale Surveillance of SARS-CoV-2 and Influenza A Viruses in Wild Mammals, United States, 2022-2023.
    Emerg Infect Dis. 2025;31:1625-1629.
    PubMed         Abstract available

  18. HATTA M, Larson GP, Hatta Y, Wang W, et al
    ACE2 Receptor Usage across Animal Species by SARS-CoV-2 Variants.
    Emerg Infect Dis. 2025;31:1640-1644.
    PubMed         Abstract available

  19. JUDGE AS, Mitchell T, Klosovsky A, Weinberg M, et al
    COVID-19 Predeparture Test Results and Vaccination Coverage among US-Bound Refugees, 2020-2022.
    Emerg Infect Dis. 2025;31:1630-1635.
    PubMed         Abstract available

  20. BRADBURNE C, Islam A, Bird I, Abbott E, et al
    Genomic Surveillance Detection of SARS-CoV-1-Like Viruses in Rhinolophidae Bats, Bandarban Region, Bangladesh.
    Emerg Infect Dis. 2025;31:1652-1656.
    PubMed         Abstract available


    Int J Infect Dis

  21. ZHANG Y, Guo J, Li Y, Song Y, et al
    Pre-pregnancy vaccination with inactivated vaccines protects SARS-CoV-2-exposed neonates from respiratory distress.
    Int J Infect Dis. 2025 Jul 16:107978. doi: 10.1016/j.ijid.2025.107978.
    PubMed         Abstract available

  22. COBO-VAZQUEZ E, Aguilera-Alonso D, Grandioso-Vas D, Gamell A, et al
    SHARP INCREASE IN THE INCIDENCE AND SEVERITY OF INVASIVE STREPTOCOCCUS PYOGENES INFECTIONS IN CHILDREN AFTER THE COVID-19 PANDEMIC (2019-2023): A NATIONWIDE MULTICENTER STUDY.
    Int J Infect Dis. 2025 Jul 16:107982. doi: 10.1016/j.ijid.2025.107982.
    PubMed         Abstract available

  23. SIEBNER AS, Griesbaum J, Huus KE, Flugge J, et al
    Class switch towards IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees.
    Int J Infect Dis. 2025 Jul 16:107990. doi: 10.1016/j.ijid.2025.107990.
    PubMed         Abstract available


    J Infect

  24. ZHANG S, Liang H, Xu J, Chen B, et al
    Spatial-temporal Dynamics and Virus Interference of Respiratory Viruses: Insights from Multi-Pathogen Surveillance in China.
    J Infect. 2025 Jul 22:106556. doi: 10.1016/j.jinf.2025.106556.
    PubMed         Abstract available


    J Med Virol

  25. MASTERS EA, Tang W, Kang I, Kosikova M, et al
    Dissecting Sex-Specific Pathology in K18-hACE2 Transgenic Mice Infected With Different SARS-CoV-2 Variants.
    J Med Virol. 2025;97:e70506.
    PubMed         Abstract available

  26. HERNANDEZ-ORTIZ OH, Naranjo AF, Cadavid JJV, Echavez GR, et al
    Risk Factors for Breakthrough Acute SARS-CoV-2 Infections in Fully Vaccinated Individuals: A Case-Control Study Nested in a Prospective Cohort in Medelln, Colombia.
    J Med Virol. 2025;97:e70508.
    PubMed         Abstract available


    J Virol

  27. LI Q, Cai X, Li X, Zhang Y, et al
    Structural and functional constraints on spike activation and host protease utilization limit cell entry of SARS-CoV-2-related bat coronaviruses.
    J Virol. 2025 Jul 24:e0100725. doi: 10.1128/jvi.01007.
    PubMed         Abstract available


    JAMA

  28. SCHNEIDER L
    WHO Report Suggests Likely Zoonotic Origin of COVID-19, Doesn't Rule Out Lab Leak.
    JAMA. 2025 Jul 25. doi: 10.1001/jama.2025.10976.
    PubMed        


    Lancet

  29. APEAGYEI AE, Bisignano C, Elliott H, Hay SI, et al
    Tracking development assistance for health, 1990-2030: historical trends, recent cuts, and outlook.
    Lancet. 2025 Jul 14:S0140-6736(25)01240-1. doi: 10.1016/S0140-6736(25)01240.
    PubMed         Abstract available


  30. Global HIV targets: a roadmap to 2030 and beyond.
    Lancet. 2025 Jul 16:S0140-6736(25)01449-7. doi: 10.1016/S0140-6736(25)01449.
    PubMed        

  31. WINKLER AS, Brux CM, Carabin H, das Neves CG, et al
    The Lancet One Health Commission: harnessing our interconnectedness for equitable, sustainable, and healthy socioecological systems.
    Lancet. 2025 Jul 14:S0140-6736(25)00627-0. doi: 10.1016/S0140-6736(25)00627.
    PubMed        


    Nature

  32. CONROY G
    People's brains aged faster during the COVID pandemic - even the uninfected.
    Nature. 2025 Jul 22. doi: 10.1038/d41586-025-02313.
    PubMed        

  33. RO C
    The COVID-19 pandemic transformed this scientist into a research-integrity sleuth.
    Nature. 2025 Jul 22. doi: 10.1038/d41586-025-01920.
    PubMed        


    Radiology

  34. KETAI L
    Post-COVID-19 Chest CT Expert Consensus, and a Nod to the Law of the Instrument.
    Radiology. 2025;316:e251890.
    PubMed        

  35. YOON SH, Kanne JP, Ashizawa K, Biederer J, et al
    Best Practice: International Multisociety Consensus Statement for Post-COVID-19 Residual Abnormalities on Chest CT Scans.
    Radiology. 2025;316:e243374.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

Stability of #influenza viruses in the #milk of #cows and #sheep

By G.M.
Abstract In late 2023, H5N1 high pathogenicity avian influenza (HPAIV) started circulating in dairy cattle in the USA . High viral titres were detected in milk from infected cows , raising concerns about onwards human infections . Although pasteurisation was shown to effectively inactivate influenza viruses in milk, unpasteurised milk still poses a risk of infection, both from occupational exposure in dairies and from the consumption of raw milk. We therefore assessed how long influenza viruses could remain infectious for in milk without heat inactivation. We examined the stability of a panel of influenza viruses in milk , including a contemporary H5N1 HPAIV and a variety of other influenza A and D viruses. We incubated viruses in cows' milk under laboratory conditions : at room temperature to simulate exposure in dairies and at 4°C to simulate exposure to refrigerated raw milk. Following an isolated report of H5N1 viral RNA being detected in milk from a sheep in the UK , we also c...
Post a Comment
Read more »

#Evidence of #Viremia in Dairy #Cows Naturally Infected with #Influenza A {#H5N1} Virus, #California, #USA

By G.M.
Abstract We confirmed influenza A virus (IAV) by PCR in serum from 18 cows on 3 affected dairy farms in California, USA . Our findings indicate the presence of viremia and might help explain IAV transmission dynamics and shedding patterns in cows. An understanding of those dynamics could enable development of IAV mitigation strategies. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/7/25-0134_article ____
Post a Comment
Read more »